Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 12424.60
AKBA's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: 12424.60 )
AKBA' s 10-Year Cash to Debt Range
Min: No Debt   Max: 12424.6
Current: 12424.6

No Debt
12424.6
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -40.38
AKBA's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: -40.38 )
AKBA' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -40.38

ROA (%) -38.68
AKBA's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: -38.68 )
AKBA' s 10-Year ROA (%) Range
Min: -71.35   Max: -71.35
Current: -38.68

ROC (Joel Greenblatt) (%) -30246.38
AKBA's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: -30246.38 )
AKBA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -106220   Max: -106220
Current: -30246.38

» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.70
AKBA's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: 3.70 )
AKBA' s 10-Year P/B Range
Min: 0   Max: 9.5
Current: 3.7

0
9.5
EV-to-EBIT 24.40
AKBA's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: 24.40 )
AKBA' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 24.4

Current Ratio 26.43
AKBA's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: 26.43 )
AKBA' s 10-Year Current Ratio Range
Min: 21.84   Max: 26.43
Current: 26.43

21.84
26.43
Quick Ratio 26.43
AKBA's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. AKBA: 26.43 )
AKBA' s 10-Year Quick Ratio Range
Min: 21.84   Max: 26.43
Current: 26.43

21.84
26.43

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare: » details
Traded in other countries:AX9.Germany
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia... Sep 25 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Sep 22 2014
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% Sep 16 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Sep 15 2014
Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors Sep 15 2014
Others Overlooked Akebia Therapeutics (AKBA), Should You Buy It Now? Sep 15 2014
Akebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell Sep 11 2014
Akebia Therapeutics (AKBA): An Off-the-Radar Potential Winner Aug 28 2014
Akebia to Participate in Upcoming Investor Conferences Aug 27 2014
Can the Uptrend Continue for Akebia (AKBA)? Aug 18 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
Akebia Announces Second Quarter 2014 Financial Results Aug 11 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Aug 06 2014
Akebia Therapeutics Announces Expansion of Management Team Aug 06 2014
Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors Jul 17 2014
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Jul 17 2014
Akebia Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes Jun 30 2014
Hidden Value From Abnormal Insider Buying Activity Jun 10 2014
Akebia Therapeutics Announces Upcoming Presentation at 51st ERA-EDTA Annual Congress May 29 2014
Akebia to Present at the Annual UBS Global Healthcare Conference May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK